Paolo Tarantino (@PTarantinoMD) ranks #1 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 189 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: SERENA-6, VIKTORIA-1, VERITAC-2 (vepdegestrant). CMS Open Payments lists $24,821 in 2025 general payments.
At a Glance
- 32 posts naming a trial in 2026
- 19 trials discussed by name
- Breast Cancer: US #1, Global #1 · 189 physicians engaged
- Leading physician voice: #1 of 39 physicians on SERENA-6; #1 of 23 physicians on SWITCH
- Presented at ESMO 2026, ASCO 2026 in 2026
- CMS Open Payments lists $24,821 in 2025 general payments.
This Month
What Paolo Tarantino has posted in the last 30 days. Updated November 10, 2026.
Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients. https://t.co/VvCfgdCBey
The SWITCH trial adds important prospective data on TOPO1 ADC sequencing. Among TOPO1-ADC pretreated pts with MBC, barely any activity was observed with a second TOPO1 ADC, with <10% ORR and <3 mo PFS, despite switching target. Payload cross-resistance dominates. #ESMOAmbassadors https://t.co/cDuYuM5qNv
#ESMO26 #ESMOAmbassadors My take on KEYNOTE B49: https://t.co/u6abclEeDO
🇨🇳HORIZON-Breast06: Trastuzumab rezatecan widely outperformed chemo in endocrine-refractory HR+ MBC (PFS 16.6 vs 6.8 months, HR 0.25, p=0<0.01). Definitely passes the truck test. No significant OS, likely due to crossover of some patients to TOPO1 ADCs. #ESMO26 #ESMOAmbassadors https://t.co/u7TsssjoiN
🇨🇳 PANKU-Breast01: the HER3-EGFR bispecific TOPO1 ADC Iza-Bren improved PFS vs chemo in HR+/HER2- MBC (OS immature). High rate of hematologic toxicity, with ~50% G3+ anemia, neutropenia and thrombocytopenia, and most patients requiring dose reductions⚠️. #ESMO26 #ESMOAmbassadors https://t.co/f1zn2X0bpe
PROs from lidERA presented by @GustavoWerutsky. Giredestrant appeared associated with comparable QoL vs standard ET. We don’t every day see a drug that improves adjuvant outcomes without adding side effect burden. #ESMO26 #ESMOAmbassadors https://t.co/aQ7Pim2d7p
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
Who Amplifies Paolo Tarantino
Physicians who reposted Paolo Tarantino’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #1 | #1 | 189 | 454 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Paolo Tarantino presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Rapid oral (4449RO)Paired-Biopsy Multi-Omic Analysis Reveals Target-Independent Mechanisms of Antibody-Drug Conjugate (ADC) Resistance in Metastatic Breast CancerSource: @weoncologists on X ↗
- ASCO 2026 · Poster (#159)Overall survival by genomic profile in HER2-positive metastatic breast cancer: A large US clinico-genomic database studySource: @dfci_breastonc on X ↗
What Colleagues Are Saying About Paolo Tarantino
2026 posts by fellow physicians that mention @PTarantinoMD, quoted word for word.
Hey @PTarantinoMD ! I guess we can say this passes the truck test? glad to see #sarcoma at the plenaries both at @ASCO and @myESMO https://t.co/Cz2xBngOCd
💯 Most exciting “sleeper” study at #ELCC26 waking us and CTLA-4 inhibition up again for a patient subset in great need for new options! One that if holds true in larger experience would definitely pass @PTarantinoMD ‘s 4-wheeled T-test! https://t.co/bSNUoyoqEZ https://t.co/CdOYylfX17
Why does T-DXd stop working? Paired biopsies before and after ADCs, presented by @PTarantinoMD at ESMO 2026, give a clear first answer: the tumor rarely loses HER2. Instead, several mechanisms coexist in the same tumor: Drug pumps up: ABCB1 rose in 5 of 7 T-DXd-treated tumors, ABCC1 in 4 of 7. Uptake down: MAN2A2, a glycosylation enzyme, fell in 5 of 7. In cell models, silencing it reduced T-DXd binding and internalization. After sacituzumab, no recurrent pattern at all. For clinic: a repeat biopsy that only re-checks HER2 will usually come back "still positive" and explain nothing. The resistance happens after the drug reaches the cell. Seven patients, hypothesis-generating. But it tells us what the next biopsy should measure. #bcsm #ESMO26 @myESMO
Beautiful presentation by @PTarantinoMD on paired pre/post biopsies on ADC Multifactorial resistance mechanisms for ADCs @OncoAlert #ESMO26 https://t.co/R1LfREtdVK
Hi @PTarantinoMD -The "Truck Test" for highly positive OS KM curve of Daraxonrasib in mPDAC. 👏👏👏 https://t.co/wyxFqrqgre
#ESMO26 @PTarantinoMD presents the novel and unique Charisma trial with matched samples starting an ADC then with PD. My take? Resistance is incredibly complex and not due to an isolated pathway. Down reg of receptor target uncommon. @OncoAlert https://t.co/F8L1zyd1OL
Trials Paolo Tarantino Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| SERENA-6 | 7 | #1 of 39 | Sep 6, 2026 |
| VIKTORIA-1 | 3 | #2 of 23 | Jul 15, 2026 |
| VERITAC-2 (vepdegestrant) | 3 | #2 of 18 | May 2, 2026 |
| SWITCH | 2 | #1 of 23 | Oct 26, 2026 |
| EVERA | 2 | #2 of 30 | Sep 30, 2026 |
| ASCENT-04 | 2 | #3 of 24 | May 31, 2026 |
| BRIDGET | 1 | #1 of 17 | Oct 26, 2026 |
| KEYNOTE-B49 | 1 | #10 of 23 | Oct 24, 2026 |
| HORIZON-Breast06 | 1 | #3 of 15 | Oct 23, 2026 |
| PANKU-Breast01 | 1 | #6 of 23 | Oct 23, 2026 |
| lidERA | 1 | #4 of 23 | Oct 23, 2026 |
| TALENT (TRIO-US B-12) | 1 | #8 of 23 | Oct 23, 2026 |
| PATINA | 1 | #14 of 21 | Oct 9, 2026 |
| HER2CLIMB-05 | 1 | #19 of 19 | Oct 8, 2026 |
| DESTINY-Lung04 | 1 | #34 of 37 | Sep 14, 2026 |
| SERENA-4 | 1 | #1 of 8 | Sep 11, 2026 |
| KEYNOTE-671 | 1 | #10 of 13 | Aug 21, 2026 |
| KEYNOTE-522 | 1 | #3 of 11 | May 30, 2026 |
| NATALEE | 1 | #9 of 46 | May 30, 2026 |
Paolo Tarantino on SERENA-6
Temperature check: ~60% of the responders feel ready to start monitoring for ESR1 emergence — though half of them would monitor less frequently than in SERENA-6. 40% remain skeptical or do not find it currently feasible. https://t.co/734sRpYtAn https://t.co/4niJMTxQEk
What is the value of intercepting molecular resistance in HR+/HER2- metastatic breast cancer? 🎙️Here, our podcast episode dissecting the SERENA6 strategy with the one and only @hoperugo Listen for free here: https://t.co/En3I9klrk9 And don’t forget to follow @breastfriendspd! https://t.co/4D2LuamB9Z
Highly impactful update from SERENA6. Very nice plateau in the PFS curves with longer follow up, and dramatic reduction in ctDNA and improvement in QoL which suggests deep benefit. Harder to interpret PFS2. Hoping to have this option available for our patients soon. #ASCO26 https://t.co/E4D3zaIaPx
Paolo Tarantino on VIKTORIA-1
Ten reasons why I would favor the gedatolisib doublet (fulvestrant/geda) over the triplet with palbo: 1) VIKTORIA-1 was not designed to compare the two geda arms — yet, the PFS improvement over fulvestrant was similar with or without palbo (HR 0.24, HR 0.33, with overlapping
BREAKING: positive results from the VIKTORIA-1 PIK3CA-mutant cohort Both the gedatolisib triplet and doublet improved PFS vs fulv/alpelisib, positioning gedatolisib as an active option irrespective of PIK3CA status. Key caveat: the weekly IV formulation. https://t.co/ZclPhQmcWl https://t.co/zb6GGg5fve
VIKTORIA-1 published in JCO, showing promising activity of fulvestrant/gedatolisib +/-palbo in PIK3CAwt HR+ MBC, at the expense of weekly IV injections (3wk on 1wk off) and most patients experiencing stomatitis. 2 treatment-related deaths with the triplet. https://t.co/HUN8hLbhXU https://t.co/TNG56669Xj
Paolo Tarantino on VERITAC-2 (vepdegestrant)
Mixed polling results on the use of vepdegestrant now that it is FDA approved https://t.co/CgTNfRmYov https://t.co/G8ZfIR9nKm
Vepdegestrant is now approved for the treatment of patients with ESR1-mutant HR+/HER2- MBC post–≥1 prior ET. It marks the first approval for a PROTAC in oncology — though its approval and efficacy are quite overlapping with oral SERDs. Will you use vepdegestrant in the clinic?
⚠️ Important to remember: 10% of patients on vepdegestrant are expected to develop QT prolongation (1.6% G3) — warranting caution in the coadministration of other QT-prolonging drugs https://t.co/mlJs7Av8fD
Paolo Tarantino on SWITCH
The SWITCH trial adds important prospective data on TOPO1 ADC sequencing. Among TOPO1-ADC pretreated pts with MBC, barely any activity was observed with a second TOPO1 ADC, with <10% ORR and <3 mo PFS, despite switching target. Payload cross-resistance dominates. #ESMOAmbassadors https://t.co/cDuYuM5qNv
We now have prospective data with TOPO1 ADC sequencing from: - SATEEN (#ESMOBreast26) - HER3-DXd (#ESMOBreast26) - SWITCH (upcoming #ESMO26) All validate prior retrospective data, showing that TOPO1 ADC resistance is not overcome by target switch. New payloads urgently needed. https://t.co/tsl3hjj9o5
Paolo Tarantino on EVERA
evERA, by @elmayermd, @stolaney1 et al, is now published in NEJM. Giredestrant outperformed SoC ET when combined with everolimus in HR+/HER2- MBC, particularly in ESR1 mutant disease. Looking forward to having this highly active combo available in clinic. https://t.co/tmEFGZGGOw https://t.co/xUx4cGRoPH
Promising PFS2 and OS data from evERA presented by @jhaveri_komal, showing clear improvement in outcomes with giredestrant/everolimus vs SoC ET/everolimus in ESR1mut disease, with a promising signal in ESR1wt patients as well. #ASCO26 https://t.co/VuVfz6Jpte
Paolo Tarantino on ASCENT-04
Similar to ASCENT-04, subgroup analysis from ASCENT-03 shows consistent PFS benefit with SG vs chemo across Trop2 expression, tBRCA status and HER2-status. Presented by Carlos Barrios #ASCO26 https://t.co/ctzzR474Hp
Subgroup analysis from ASCENT-04 presented by @stolaney1. Consistent PFS benefit from SG/pembro (vs chemo/pembro) across Trop2 expression, tBRCA status and HER2 IHC status. #ASCO26 https://t.co/OoFr2PDnCF
Paolo Tarantino on BRIDGET
Primary results from BRIDGET ph2 trial presented by @drsarahsam and published in @ESMO_Open. Adding tucatinib to HP after an isolated intracranial PD led to impressively long PFS (59% free from PD or death at 18mo!!). Reasonable strategy from next Monday in TKI-naive patients. https://t.co/VvCfgdCBey
Paolo Tarantino on KEYNOTE-B49
#ESMO26 #ESMOAmbassadors My take on KEYNOTE B49: https://t.co/u6abclEeDO
Paolo Tarantino’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Only few days to #ASCO26. For breast oncologists, this edition will deliver a new promising biomarker to spare unnecessary chemo, informative updates from practice-changing trials across subtypes, and major innovations coming from China. See you in Chicago next week! #bcsm https://t.co/C3dABrBnnu
We’ve long treated HER2+ breast cancer similarly. Until everything changed. Within 1 year, T-DXd moved earlier, palbo and tucatinib reshaped maintenance, some chemos are nearly gone, biomarkers guide us. The right-sizing era for HER2+ BC has begun. https://t.co/0vIg47n8RD 🧵1/ https://t.co/Py652fFBPx
The most important breast abstract from #ASCO26 is out. 4429 pts with ER+/HER2- BC randomized to SoC vs PAM50-directed adjuvant treatment. 19% had N2 dz (4-9 nodes), premenopausal pts received LHRHa. No benefit from chemo if ROR≤60. Looking forward to the full presentation. https://t.co/qX8HnKyBne https://t.co/rAnA0ULjic
Truck test ✅✅✅ https://t.co/xjBOTx1iC9 https://t.co/XifaBmZqjb
Adjuvant T-DXd is approved for pts with HER2+ BC and high-risk RD by DB05 criteria. What about pts with lower risk RD? We looked at ~10.000 pts in Flatiron, finding that 52% have low-risk RD, with 3yr DRFS 94%, suggesting that T-DM1 remains an adequate SoC for them. #ASCO26 Ab545 https://t.co/95xFq5O3Gq
Industry Payments
CMS Open Payments · 2025 general payments
$24,821 across 46 payments